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Abstract
Minimally invasive technologies for intracranial lesions are a rapidly growing 
area of surgical neuro-oncology. Magnetic resonance (MR)-guided laser interstitial 
thermal therapy (LITT) is novel adjunctive therapy for patients who are poor 
candidates for open surgical resection. Recent developments in modern stereotaxy, 
fiber optics, and MR thermography imaging have improved the safety profile 
of LITT, enabling its emergence as an attractive alternative adjunct therapy for 
intracranial lesions which are deep-seated, refractory to standard therapies, or in 
patients with multiple comorbidities. In this chapter, we review the technological 
principles underlying LITT and provide a comprehensive, up-to-date summary 
of the evidence regarding the indications, outcomes, and limitations of LITT for 
a diverse array of intracranial tumors, including dural-based lesions, metastases, 
gliomas, and radiation necrosis.
Keywords: LITT, laser, glioma, glioblastoma, astrocytoma, ablation
1. Introduction
1.1 LITT surgical procedure and current commercial platforms
LITT is a minimally invasive neurosurgical technique that delivers focused 
thermal energy from a laser light source via a fiber optic ensheathed in a cath-
eter targeted to an intracranial lesion under stereotactic neuronavigation [1–6]. 
Currently, there are two Food and Drug Administration (FDA)-approved LITT 
platforms available for use in the United States: the Visualase Thermal Therapy 
System (Medtronic, Inc.; approved in 2009) and the Neuroblate Laser Ablation 
System (Monteris, Inc.; approved in 2007).
The Visualase and Neuroblate LITT platforms share similar components 
and a standardized general workflow. The patient is first induced under general 
anesthesia or monitored anesthesia care (MAC). The trajectory for stereotactic 
placement of the laser catheter is planned using standard neuronavigation 
technology with preoperative T1-weighted gadolinium enhanced magnetic 
resonance imaging (MRI) studies. The trajectory should be planned so that the 
catheter traverses the longest axis of the lesion without risking injury to any critical 
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structures. Stereotactic registration of the laser catheter and trajectory planning can 
be performed using either a traditional headframe or frameless setup. Frameless 
stereotaxy requires an additional computed-tomography (CT) with fiducial 
markers, which is then merged with the pre-operative MRI for registration with 
neuronavigation.
Following stereotactic registration, a Precision Aiming Device (PAD) is 
aligned over the planned skull entry site using neuronavigation. A single 4 mm 
skin incision and burr hole is made over the entry point. The surgeon may elect 
to perform a concurrent needle biopsy for histopathological diagnosis. After this, 
a reducing cannula followed by the laser catheter is inserted through this burr 
hole using the PAD to ensure proper entry angle to follow the planned trajectory. 
Once the laser applicator probe’s position is fixed using a plastic anchor bolt 
embedded in the skull, the patient is transferred, under anesthesia, to a MRI suite. 
Care is taken to prevent contamination in the operating room until T2 weighted 
MRI confirms the correct placement of the laser fiber. Then, near-infrared laser 
light (980 nm in the Visualase, system, 1064 nm in the Neuroblate system) is 
delivered through the fiber optic cable within the applicator probe to the target 
lesion. Following LITT treatment, the catheter is removed and the stab incision is 
closed with absorbable sutures. An example of the Visualase LITT catheter after 
stereotactic placement is shown in Figure 1.
The delivery of thermal energy to the intracranial target is controlled by 
several mechanisms. The fiber optic laser catheter is encased in a cooling sheath, 
through which cooled saline (in the Visualase system) or a C02 gas (in the 
Neuroblate system) is circulated. This mechanism prevents the heating of brain 
parenchyma along the catheter path so that thermal damage is restricted to the 
region surrounding the distal tip [7]. At the distal tip, the distribution of laser light 
to surrounding target tissue is controlled via a diffusing tip to produce a spherical 
zone of ablation centered at the tip. Available only in the NeuroBlate system, laser 
light can be delivered through a small aperture along the lateral surface of the distal 
catheter to provide a cone-shaped region of directional ablation.
Finally, real-time MR thermography is performed concurrently with laser 
ablation to generate a thermal damage estimate (TDE) heat map, i.e., a color-coded 
visual representation of cumulative thermal damage to structures on a T2-weighted 
MRI (Figure 2).
Figure 1. 
(A) Intraoperative setup showing precision aiming device (PAD) (white arrow) and stealth neuronavigation 
wand (Medtronic, Inc.) to set laser catheter trajectory. (B) MRI-compatible laser catheter and plastic bone 
anchor after stereotactic PAD-assisted intracranial placement.
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A computer workstation has software that allows the user to adjust laser output 
parameters and deliver laser energy in a series of doses until the TDE map covers 
the total area of the target. This is typically achieved with 10–15 W doses of laser 
light delivered in 30s–3 minutes intervals for a total of 10–30 minutes. The user 
also sets minimum and maximum temperature threshold markers on MR images 
defining the boundaries of the lesion. Minimum temperature markers ensure that 
temperatures sufficient for ablation are achieved within the target lesion volume 
(50–90°C), while maximum temperature thresholds ensure that off-target regions 
do not reach damaging temperatures [8]. Surpassing the maximum temperature 
threshold triggers automatic system shutoff [9]. The majority of patients have a 
hospital stay less than 48 hours following LITT [8–11].
Post-operative T1-weighted gadolinium enhanced MRI is typically obtained on 
day one following LITT, 1–3 months post-operatively, and then at longer follow-up 
intervals depending on clinical status. There is a typical radiographic increase 
in size of the ablated lesion in the acute period following LITT, peaking around 
3–4 days and reaching a 45% increase in cross-sectional area corresponding to a 
75% increase in volume [12, 13]. The initial increase in size seen within the first 
24 hours post-op likely represents the tendency to “over-ablate” lesions and is 
secondary to perilesional edema that is difficult to differentiate radiographically. 
A significant amount of size variability is also seen in these newly ablated 
lesions and is attributed to multiple factors including heterogeneous gadolinium 
dispersion during the ablation process, heterogeneous disruption of vascular 
integrity, and the “extreme” variability in the amount of edema surrounding 
the lesion. These findings clearly lead to imaging heterogeneity and suggest that 
an accurate measurement of the lesion would be difficult to obtain in the first 
24 hours post-LITT. Therefore, it has been suggested that MRI is more accurate at 
determining LITT ablation size and shape at 24 hours post-ablation rather than 
immediately post-LITT.
On T1-weighted gadolinium enhanced MRI, the thermal ablation zone has a 
thin enhancing rim with potential surrounding edema and enhancing residual 
blood products/protein coagulation [8]. Residual tumor remaining after subtotal 
ablation can be detected on this first post-operative scan. The extent of ablation 
can be determined by comparing volumetric analysis of the ablation zone post-
operatively to the volume of the lesion on the pre-operative MRI, as described 
previously [14].
Figure 2. 
(A) Real-time MR thermography provides a continuously updated heat map with concentric temperature 
zones. (B) Thermal damage estimate (TDE) mapping for LITT. Orange pixels estimate a zone of ablation 
based on a user-set threshold for sufficient ablation temperature (typically 50°C).
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2. Current applications of LITT in neuro-oncology
2.1 Patient selection
LITT offers a minimally-invasive cytoreductive therapy for patients with 
surgically-inaccessible or treatment-refractory tumors who would likely not benefit 
from open surgical resection. Selection of appropriate cases for LITT is of primary 
concern. Over the past two decades, the first institutional experiences with LITT 
using MR thermography and modern stereotactic targeting were published, dem-
onstrating both representative successes and complications associated with the 
procedure, including post-operative symptomatic edema, neurological deficit, and 
hemorrhage [4, 8, 15]. These results signaled the need to refine patient selection 
criteria to maximize changes of treatment success while minimizing risk of compli-
cations. From these initial studies in addition to our own institutional experiences 
[14, 16–18], we can summarize the following indications for LITT:
1. Anatomic location permits a reasonable expectation of an 80% ablation in 
order to confer a significant survival benefit [16, 19–21].
2. Lesion location is inaccessible via conventional open surgery (e.g., lesions 
located adjacent to deep structures such as the basal ganglia, thalamus, sple-
nium, etc., in eloquent motor or speech areas, or near critical neurovascular 
structures).
3. Lesions have failed previous treatments (i.e., previous craniotomy or 
radiation).
4. Patients have medical comorbidities, low pre-operative functional status, or 
history of previous craniotomy/radiation therapy who are unable to tolerate 
prolonged anesthesia, blood loss, or who are at high risk of surgical morbidity 
and impaired wound healing.
5. Pediatrics: although cases must be carefully selected, there are currently no 
changes in protocol for the use of LITT in pediatric neurosurgery.
Additionally, we can summarize the following restrictions to best avoid proce-
dural complications:
1. Functional status: patients should still have a pre-operative functional status 
appropriate for a minimally-invasive surgical procedure under anesthesia; 
in our institutional experience, patients are eligible if they have a Karnofsky 
Performance Score (KPS) of at least 70.
2. Lesion size: LITT should be limited to lesions with <3 cm diameter in any 
dimension. This size restriction stems from Jethwa et al., who reported the case 
of patient with a large (>3 cm) lesion treated with LITT who later underwent 
hemicraniectomy for medically-refractory post-ablation edema [8]. The <3 cm 
guideline also reduces risk of damage to critical brain regions.
3. LITT trajectory: careful precautions must be made while choosing a trajec-
tory to avoid critical neurovascular structures. In some cases, passing through 
virgin white matter should take priority over creating the shorter trajectory if 
the shortest trajectory involves eloquent tissue.
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In the following sections we review the current state of LITT for treatment for a 
variety of intracranial tumors.
2.2 Glioma
Recent studies have shown that greater extent of surgical resection improves 
progression-free and overall survival in high-grade gliomas (HGGs) [22, 23]. 
Although HGGs inevitably recur, some patients may not be able to undergo con-
ventional open surgical resection due to medical comorbidities, inability to tolerate 
general anesthesia, or have surgically inaccessible tumor locations. In addition, risk 
of neurological morbidity increases with repeat craniotomy and previous radiation 
therapy increases risk of impaired wound healing and radiation necrosis or second-
ary tumor formation [24]. Up to 40% of GBM tumors are considered surgically 
“unresectable” based on either their location in deep or eloquent brain regions or 
their proximity to critical neurovascular structures [14, 25]. For these patients, 
laser interstitial thermal therapy (LITT) provides an alternative option for cytore-
ductive therapy.
The first case series reporting the use of LITT in gliomas was published in 1990 
by Sugiyama et al., which described the successful total ablation of five deep-seated 
gliomas. This has been followed by several larger case series for both recurrent 
and newly-diagnosed glioblastoma multiforme (GBM) [8, 10, 11, 15, 26–30]. In 
these series, median recurrence-free survival ranged from 1.5 to 14.3 months and 
overall survival ranged from 6.9 to 16 months. These reports are consistent with 
estimated median survival of 14.8 and 6 months for newly-diagnosed and recur-
rent gliomas under standard therapy, respectively [31]. Our institutional data for 
deep-seated (at least 2 cm from dura) newly diagnosed gliomas further evidenced 
the procedural safety and efficacy in 7 patients, with a median progression-free 
survival of 14.3 months and 85% patients remaining alive at 14 months follow-up. 
As such, LITT is an emerging safe adjuvant therapy for gliomas that are considered 
surgically inaccessible. A recent meta-analysis reported an overall survival of nearly 
14 months (range: 0.1–23 months) for patients treated with LITT and adjuvant 
chemoradiation, which was comparable to reported outcomes after standard treat-
ment (gross total resection and adjuvant chemoradiation) [16, 32–34].
2.3 Dural-based lesions
Although evidence is more limited for dural-based lesions, the published studies 
to date support the safety and efficacy of LITT for these lesions. An initial case 
series by Ivan et al. reported outcomes in 5 patients with 3 recurrent low-grade 
meningiomas, 1 grade III malignant meningioma, and 1 solitary fibrous tumor. Ivan 
et al. report an average extent of ablation of 80% and a local control rate of 60% at 
a mean follow-up of 59.3 weeks. The procedure was well-tolerated in these patients 
with no complications reported [18]. Only one other case series of three patients 
has been reported [35]. Two patients had grade III anaplastic meningiomas while 
the third had a low-grade lesion. The authors report an average extent of ablation 
of 75% with 2 of 3 lesions recurring by 9 weeks. One patient experienced transient 
hemiparesis with dysarthria, which resolved.
In comparison to other reports of LITT for intracranial lesions, these stud-
ies report lower extent of ablation rates, which may be attributable to tissue 
consistency. In these studies, the presence of a grade III malignant meningioma 
complicates the picture regarding the efficacy of LITT for dural-based lesions. 
Nonetheless, the procedure is generally well-tolerated, justifying further investiga-
tion into its utility for these lesions.
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2.4 Brain metastases
LITT is a promising adjuvant therapy for recurrent brain metastases refractory 
to stereotactic radiosurgery (SRS). The first case series of LITT for brain metastases 
was reported by Carpentier et al. [41]. A subsequent Phase I clinical trial by the 
same authors, published in 2011, reported 6-month local control rates of 60 and 
85% for partially and fully-ablated metastatic tumors, respectively [36]. In 2016, Ali 
et al. identified an 80% extent of ablation threshold, below which all cases eventu-
ally recurred [37]. Similarly, Ahluwalia et al. reported a 0% recurrence rate in 
100% ablated lesions [38]. A recent systematic review found that reports of median 
overall survival after LITT for metastases ranged from 5.8 to 19.8 months [39]. 
Across studies, the most commonly reported complications were temporary neuro-
logic deficit due to unintentional thermal ablation of eloquent structures, followed 
by hemorrhage. Although a 1–3 day period of post-operative edema on T2 FLAIR 
MRI sequences frequently occurs post-ablation, this typically resolves. In four rare 
instances of malignant edema requiring hemicraniectomy, the lesion volumes were 
far greater than 3 cm in diameter [39]. These recent studies support that LITT is safe 
and effective in cases where 80–100% lesional ablation can be achieved.
2.5 Radiation necrosis
LITT was first described for radiation necrosis (RN) by Rahmathulla et al. 
[40]. In this report, a single patient presented with progressive dysphagia follow-
ing radiosurgery for brain metastasis almost 2 years prior. Because the symptoms 
did not respond to medical management with steroids, he was treated with 
LITT. Following LITT, he achieved steroid independence [40]. This study was fol-
lowed by larger single-center retrospective case series which reported use of LITT 
for radiation necrosis with initial diagnoses of glioma or metastases. In these studies 
<50% of patients achieved steroid freedom, and up to 20% of patients required 
open craniotomy for surgical resection in the months following LITT [38]. In a 
study of LITT for radiation necrosis or post-radiosurgery recurrent metastasis, Rao 
et al., reported a median progression-free survival of 37 weeks with only 2 recur-
rences in 15 patients [5]. The authors concluded that LITT is a safe, well-tolerated 
procedure for patients with radiation necrosis or metastatic recurrence.
Our institutional experience with 20 patients with biopsy-proven RN between 
2015 and 2018 also supports these conclusions (unpublished data). At 1 year 
follow-up, 80% of patients remained recurrence free, with a median progression-
free survival of 12.3 and 24.4 months overall survival. No permanent complications 
occurred (unpublished data).
Overall evidence supports LITT as a safe procedure for radiation necrosis that is 
medically refractory or surgically inaccessible. In these patients, steroid freedom as 
well as progression-free and overall survival are important clinical outcomes.
3. Illustrative case series
Here we present four cases of patients treated by the department of surgical 
neuro-oncology at the University of Miami illustrating the use of LITT for gliomas, 
dural-based lesions, brain metastases, and radiation necrosis.
3.1 Case 1: recurrent glioma
A 37-year-old female with previous history of left frontoparietal craniotomy 
and chemoradiation for high-grade glioma 2 years prior presented with progressive 
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enhancement on surveillance MRI suggesting recurrence (Figure 3A). The patient 
was recommended LITT due to the lesion’s proximity to the left motor strip. The 
lesion was ablated according to the following parameters:
1. Test dose at 3 W for 30 seconds to confirm location of catheter tip on MR 
thermography.
2. Increase in laser power to 50% maximum power for up to 3 minutes.
3. Increase in laser power at 20% maximum intervals for 30 seconds—1.5 min-
utes in series until maximal ablation zone is achieved (Figure 3B).
The patient recovered without complications. Although some residual tumor 
was present on postoperative imaging (Figure 3C), the patient remained recurrence 
free for 24.3 weeks with an overall survival of 1 year.
3.2 Case 2: meningioma
A 65-year-old female with previous history of craniotomy for resection of a 
right parafalcine meningioma and subsequent craniectomy for a wound infection 
Figure 3. 
(A) A 37-year-old female with periventricular ring-enhancing mass abutting the left motor strip on axial 
T1-weighted MRI with contrast. (B) Intraoperative sagittal MRI showing laser catheter trajectory. (C) 
Immediate post-operative axial T1-weighted MRI with contrast demonstrating near-total lesional ablation.
Figure 4. 
(A) Pre-operative T1-weighted MRI with contrast showing recurrence of right parafalcine meningioma.  
(B) Post-operative T1-weighted MRI with contrast showing near-total lesional ablation.
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at an outside institution presented with progressive lesion regrowth over several 
MRI studies (Figure 4A). Because of her complicated surgical history, she was 
recommended LITT. Postoperative MRI imaging showed 97% extent of ablation 
(Figure 4B) and the patient recovered without complications. Patient remained 
recurrence free until non-neurologic death 4 years later.
3.3 Case 3: metastasis
A 31-year-old female with past medial history of metastatic breast cancer 
previously treated with whole brain radiation and stereotactic radiation for five 
intracranial metastatic lesions. She presented with headaches photophobia, dizzi-
ness, and fatigue. T1-weighted gadolinium enhanced MRI showed interval growth 
of one lesion in the right parietal lobe. Due to her extensive previous radiation 
history and the proximity of the lesion to the receptive speech area of the poste-
rior left temporal lobe, the patient was treated with LITT, achieving near-total 
Figure 6. 
(A) A 69-year-old female patient with progressive enhancement after treatment of metastatic lung 
adenocarcinoma. (B) Post-LITT procedure T1-weighted MRI with contrast shows successful lesion ablation.
Figure 5. 
(A) A 31-year-old female patient with recurrent metastatic breast cancer adjacent to the receptive speech area 
of the posterior temporal lobe. (B) Post-LITT procedure T1-weighted MRI shows lesional ablation.
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ablation (Figure 5B). Patient remained recurrence free until last follow-up at 
16 months post-procedure.
3.4 Case 4: radiation necrosis
A 69-year-old woman with history of metastatic lung adenocarcinoma previ-
ously treated with open surgical resection and stereotactic radiosurgery presented 
with asymptomatic progressive enhancement on surveillance MRI (Figure 6A). 
Because of her treatment history, the patient elected to undergo LITT. Patient 
recovered without complications and remained recurrence free at last follow-up, 
over 1 year after LITT (Figure 6B). Intraoperative needle biopsy performed prior to 
laser catheter placement confirmed diagnosis of radiation necrosis.
4. Discussion
4.1 Current role of LITT in neurosurgery
Technological advances in MR thermography and stereotactic surgery over the 
past two decades have facilitated the development of commercial LITT platforms. 
Evidence from both prospective and retrospective studies show that LITT is a safe 
alternative for cytoreduction in a wide variety of intracranial lesions, including 
metastases, radiation necrosis, dural-based lesions, and gliomas.
The advantage of LITT in treating intracranial lesions include:
1. Cytoreductive therapy in poor open-surgical candidates: a minimally invasive 
approach through a single burr hole reduces the risk of morbidity associated 
with craniotomy for surgical resection. This is especially relevant for patients 
who previously underwent open craniotomy or maximal radiotherapy, who 
are at higher risk of neurological sequelae and wound infection with repeat 
craniotomy [21, 24] or in patients with tumors in deep or eloquent regions of 
brain that would otherwise be considered surgically inaccessible.
2. Short procedure time: LITT has a shorter procedure time compared to open 
craniotomy. With shorter recovery times, LITT does not interrupt chemo-
therapy or other adjuvant therapy [10, 17].
3. Potential for repeated use: unlike stereotactic radiosurgery, LITT can be 
repeatedly applied and can thus be used as a salvage therapy in treatment-
refractory tumors while avoiding the increased risk of secondary malignancy 
or radiation necrosis associated with ionizing radiation [7, 16].
Patient selection is of critical importance to ensure safe and effective use of 
LITT. To summarize, lesions should be <3 cm in diameter, in a region that can be 
accessed via a linear laser catheter trajectory without injury to critical structures and 
in patients who are able to tolerate a minimally-invasive surgical procedure under 
anesthesia. In addition, the lesion should have identifiable margins such that at least 
80% of the target area can be feasibly ablated with a roughly-spherical ablation zone.
4.2 Limitations of LITT
Limitations of LITT include complications; the most common adverse events 
include intracranial hemorrhage and transient neurological deficit [10, 39, 41]. 
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Intracranial hemorrhage may be secondary to laser catheter misplacement, off-
target thermal ablation, or (in the case of brain metastases) an underlying patient 
coagulopathy [8, 39, 42]. This risk can be reduced with preoperative neuroimaging 
(e.g., computed tomography angiogram (CTA)) to better inform laser trajectory 
planning. Estimates of hemorrhage range from 0.98 to 14.2% of cases [39, 42].
Permanent neurological deficits are rare [42], but transient neurological deficits 
have been reported to occur in up to 35% of patients [39, 42]. Examples of com-
monly reported neurological deficits include weakness, hemianopsia, seizures, and 
dysphagia are often attributed to direct thermal injury to functional brain areas or 
cerebral edema. Cerebral edema is frequently observed in the immediate post-oper-
ative period following LITT, but is unlikely to cause permanent neurological deficits 
and may be controlled with a short course of steroids. Treatment of large (>3 cm) 
or use of multiple laser probes or laser trajectories is associated with a higher risk of 
significant cerebral edema [43].
Rare (<5% of all cases) complications include permanent neurological deficit, 
malignant cerebral edema requiring hemicraniectomy, infection (e.g., ventriculitis, 
meningitis, or brain abscess), diabetes insipidus, hyponatremia, and intracranial 
hypertension. There are only two recorded deaths attributed to LITT in the litera-
ture, from postoperative meningitis and intracranial hemorrhage, respectively [44].
Another limitation of LITT is that it is only appropriate for certain patients. As 
discussed previously, previous treatment history, baseline neurological functional 
status, and anticipated extent of ablation are also factors that limit use of LITT to 
selected patients.
4.3 Future directions
Recent studies have focused on expanding the selection criteria for LITT, for 
example by staging the treatment of larger (>3 cm) lesions and application to other 
tumors, such as pediatric tuberous sclerosis and hypothalamic hamartomas [45]. 
In addition, the application of computer algorithms to better predict laser ablation 
dynamics may further improve the procedural safety profile [46].
Another body of research is investigating the secondary effects of LITT, includ-
ing blood–brain barrier (BBB) disruption, which may offer a window of opportu-
nity for enhanced delivery of chemotherapy [47, 48]. Other studies are investigating 
the potential immunostimulatory effects of LITT [49, 50]. In this sense, LITT could 
both ablate and facilitate a future antitumor immune response [51].
Finally, future investigations will require prospective, randomized-controlled 
trials to evaluate the clinical outcomes of LITT compared to other salvage therapies, 
such as repeat craniotomy or radiosurgery.
5. Conclusion
In this chapter we reviewed the current evidence regarding safety and efficacy of 
LITT for four types of intracranial lesions: gliomas, metastases, dural-based lesions, 
and radiation necrosis. Although future randomized controlled trials are necessary 
to compare clinical outcomes, the evidence so far supports LITT as a safe and viable 
minimally-invasive approach to cytoreduction in patients with gliomas that are poor 
open surgical candidates.
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